DrugPatentWatch Database Preview
Neurocrine Company Profile
What is the competitive landscape for NEUROCRINE, and what generic alternatives to NEUROCRINE drugs are available?
NEUROCRINE has one approved drug.
There are three US patents protecting NEUROCRINE drugs.
There are thirty patent family members on NEUROCRINE drugs in eighteen countries.
Summary for Neurocrine
| International Patents: | 30 |
| US Patents: | 3 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Neurocrine
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-002 | Oct 4, 2017 | RX | Yes | Yes | 8,357,697 | Start Trial | Start Trial | ||||
| Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-001 | Apr 11, 2017 | RX | Yes | No | 10,065,952 | Start Trial | Y | Y | Start Trial | ||
| Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-002 | Oct 4, 2017 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Neurocrine Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 101500766 | Start Trial |
| Israel | 198250 | Start Trial |
| South Korea | 20180075591 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
